<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="156396">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01063751</url>
  </required_header>
  <id_info>
    <org_study_id>69</org_study_id>
    <nct_id>NCT01063751</nct_id>
  </id_info>
  <brief_title>Tritanium® Primary Acetabular Shell Study</brief_title>
  <official_title>A Prospective, Post-market, Multi-center Study of the Tritanium® Acetabular Shell</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stryker Orthopaedics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stryker Orthopaedics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be a prospective, non-randomized evaluation of the Tritanium® Acetabular
      Shell for primary total hip replacement (THR) with a cementless application in a consecutive
      series of patients who meet the eligibility criteria. Half of the cases will use the X3®
      polyethylene insert alone as the bearing surface; the other half will use the MDMTM liner
      coupled with a compatible ADM/MDMTM X3® insert as the bearing surface.

      The success rate, defined as freedom from acetabular revision for any reason, for hips
      implanted with the Tritanium® Acetabular Shell, is no worse than for hips implanted with
      similar technology as reported in the literature and Trident® X3® Study historical control
      at 5 years postoperative.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Anticipated">November 2026</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absence of acetabular revision</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rates of Screw Fixation Usage in the Triathlon Acetabular Shell</measure>
    <time_frame>Intraoperative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Harris Hip Score</measure>
    <time_frame>1, 3, and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-12 Heath Survey Scores</measure>
    <time_frame>1, 3, and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lower Extremity Activty Scale (LEAS) Score</measure>
    <time_frame>1, 3, and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ-5D</measure>
    <time_frame>1,2,3,4, and 5 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Follow-Up Questionnaire</measure>
    <time_frame>6, 7, 8, 9, 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acetabular Shell Radiographic Stability</measure>
    <time_frame>6 weeks, 1, 3, 5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">240</enrollment>
  <condition>Arthroplasty, Replacement, Hip</condition>
  <arm_group>
    <arm_group_label>Tritanium® Primary Acetabular Shell</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Tritanium® Primary Acetabular Shell</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Tritanium® Primary Acetabular Shell</intervention_name>
    <description>Tritanium® Primary Acetabular Shell in total hip replacement.</description>
    <arm_group_label>Tritanium® Primary Acetabular Shell</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A. Patient has signed an IRB approved, study specific Informed Patient Consent Form.

          -  B. Patient is a male or non-pregnant female age 18 years or older at time of study
             device implantation.

          -  C. Patient has primary diagnosis of Non-Inflammatory Degenerative Joint Disease
             (NIDJD).

          -  D. Patient is a candidate for a primary cementless total hip replacement.

          -  E. Patient is willing and able to comply with postoperative scheduled clinical and
             radiographic evaluations and rehabilitation.

        Exclusion Criteria:

          -  F. Patient has a Body Mass Index (BMI) ≥ 40.

          -  G. Patient has an active or suspected latent infection in or about the affected hip
             joint at time of study device implantation.

          -  H. Patient has a neuromuscular or neurosensory deficiency, which limits the ability
             to evaluate the safety and efficacy of the device.

          -  I. Patient is diagnosed with a systemic disease (e.g. Lupus Erythematosus) or a
             metabolic disorder (e.g. Paget's Disease) leading to progressive bone deterioration.

          -  J. Patient is immunologically suppressed or receiving steroids in excess of normal
             physiological requirements (e.g. &gt; 30 days).

          -  K. Patient requires revision surgery of a previously implanted total hip replacement
             or hip fusion to the affected joint.

          -  L. Patient has a known sensitivity to device materials.

          -  M. Patient is a prisoner.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timothy H Izant, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Crouse Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Noble, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Christus St. Patrick Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ron James, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mercy General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Bradford, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Eastern Maine Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dan Del Gaizo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of North Carolina</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Diana, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Helena Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daniel Ward, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New England Baptist</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tharun Karthikeyan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Joseph Hospital Health Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephen Duncan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kentucky Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Brock Lindsey, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>West Virginia University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephen Raterman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Florida Hospital Wesley Chapel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mercy Medical Group</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95816</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coon Joint Replacement Institute</name>
      <address>
        <city>St. Helena</city>
        <state>California</state>
        <zip>94574</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Medical Clinic</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33542</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unversity of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Imperial Calcasieu Medical Group</name>
      <address>
        <city>Lake Charles</city>
        <state>Louisiana</state>
        <zip>70601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastern Maine Medical Center</name>
      <address>
        <city>Bangor</city>
        <state>Maine</state>
        <zip>04401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Syracuse Orthopedic Specialists</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Virginia University</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>November 16, 2016</lastchanged_date>
  <firstreceived_date>February 4, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Osteoarthritis</keyword>
  <keyword>Traumatic arthritis</keyword>
  <keyword>Avascular Necrosis</keyword>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
